Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines is a research paper published in PLoS Medicine (2020). On theSindex it has a DataRank of 1.2. It has been cited 48 times, with 34 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.584
From this paper's citation signal
Citation Network Contribution
0.578
From 23 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 34 citers.
National Institute of Allergy and Infectious Diseases
Grant: UM1 AI068614
National Institute of Allergy and Infectious Diseases
Grant: UM1 AI068618
National Institute of Allergy and Infectious Diseases
Grant: UM1 AI068635
National Institute of Allergy and Infectious Diseases
Grant: UM1 AI069453
National Institute of Allergy and Infectious Diseases
Grant: UM1 AI069519
National Institute of Allergy and Infectious Diseases
Grant: UM1 AI069469
National Institute of Allergy and Infectious Diseases
Grant: UM1 AI069422
Bill and Melinda Gates Foundation
Grant: OPP1110792
National Institute of Allergy and Infectious Diseases
Grant: HHSN272201300033C//HHSN272201600012C
Bill and Melinda Gates Foundation
Grant: OPP1017604
NIAID NIH HHS
Grant: HHSN272201300033C
NIAID NIH HHS
Grant: U01 AI069519
NIMH NIH HHS
Grant: R21 MH083308
NIAID NIH HHS
Grant: HHSN272201600012C
National Institutes of Health
Grant: 5UM1AI069519-16
HIV/AIDS Clinical Trials Units University of Cape Town CTU 2020 to 2027
National Institutes of Health
Grant: 5UM1AI069469-10
CAPRISA Clinical Trials Unit for AIDS/Tuberculosis Prevention and Treatment
National Institutes of Health
Grant: 3UM1AI068614-15S2
CoVPN 3005 - Efficacy, Immunogenicity, and Safety of SARS-CoV-2 Recombinant Protein Vaccine with Adjuvant in Adults 18 Years of Age and Older
National Institutes of Health
Grant: 4UM1AI069453-07
Soweto Clinical Trials Unit
National Institutes of Health
Grant: 2UM1AI069519-15
HIV/AIDS Clinical Trials Units University of Cape Town CTU 2020 to 2027
National Institutes of Health
Grant: 3UM1AI068635-17S4
CoVPN 3001 - A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults.
National Institutes of Health
Grant: 3UM1AI068635-15S3
CoVPN Cross-Protocol Analyses
National Institutes of Health
Grant: 5UM1AI069422-13
South African Medical Research Council Clinical Trials Unit (MRC CTU)
National Institutes of Health
Grant: 5UM1AI068618-14
LC: HIV Vaccine Trials Network
National Institutes of Health
Grant: 3UM1AI068618-16S1
HVTN 405/HPTN 1901 (CoVPN) Characterizing SARS-CoV-2-specific Immunity in Convalescent Individuals: LC 3
FWCI
3.39
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals